Home
SGMT
SGMT News

Latest Sagimet Biosciences Inc. Series A (SGMT) News on May 9, 2025

Sagimet Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Updates

GlobeNewswire

a day ago

Sagimet Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Updates

Top Penny Stocks To Watch In April 2025

Simply Wall St.

15 days ago

Top Penny Stocks To Watch In April 2025

Sagimet Biosciences Announces Upcoming Presentations at EASL Congress 2025

GlobeNewswire

16 days ago

Sagimet Biosciences Announces Upcoming Presentations at EASL Congress 2025

Sagimet Biosciences Reports Full Year 2024 Financial Results and Provides Corporate Updates

GlobeNewswire

2 months ago

Sagimet Biosciences Reports Full Year 2024 Financial Results and Provides Corporate Updates

MT Newswires

2 months ago

Sagimet Reports Acne Drug Candidate Cleared for Clinical Trials

Sagimet Biosciences Announces Clearance of IND for FASN Inhibitor TVB-3567, to be Developed for the Treatment of Acne

GlobeNewswire

2 months ago

Sagimet Biosciences Announces Clearance of IND for FASN Inhibitor TVB-3567, to be Developed for the Treatment of Acne

Is Sagimet Biosciences Inc. (SGMT) the Best Get Rich Quick Stock to Invest In?

Insider Monkey

2 months ago

Is Sagimet Biosciences Inc. (SGMT) the Best Get Rich Quick Stock to Invest In?

Sagimet Biosciences Inc. (SGMT): Among the Hot Penny Stocks to Buy Now

Insider Monkey

3 months ago

Sagimet Biosciences Inc. (SGMT): Among the Hot Penny Stocks to Buy Now

Sagimet Biosciences Announces Oral Presentation at the MASH Pathogenesis and Therapeutic Approaches Keystone Symposium

GlobeNewswire

3 months ago

Sagimet Biosciences Announces Oral Presentation at the MASH Pathogenesis and Therapeutic Approaches Keystone Symposium

US Penny Stocks Spotlight: Gevo And 2 Other Promising Picks

Simply Wall St.

3 months ago

US Penny Stocks Spotlight: Gevo And 2 Other Promising Picks

Sagimet Biosciences Announces Oral Presentation at the 9th Annual MASH-TAG 2025 Conference

GlobeNewswire

4 months ago

Sagimet Biosciences Announces Oral Presentation at the 9th Annual MASH-TAG 2025 Conference

Sagimet Biosciences (NASDAQ:SGMT) Is In A Good Position To Deliver On Growth Plans

Simply Wall St.

4 months ago

Sagimet Biosciences (NASDAQ:SGMT) Is In A Good Position To Deliver On Growth Plans

Oppenheimer Predicts Up to ~580% Jump for These 2 ‘Strong Buy’ Stocks

TipRanks

5 months ago

Oppenheimer Predicts Up to ~580% Jump for These 2 ‘Strong Buy’ Stocks

Sagimet Biosciences to Participate in the Piper Sandler 36th Annual Healthcare Conference

GlobeNewswire

5 months ago

Sagimet Biosciences to Participate in the Piper Sandler 36th Annual Healthcare Conference

Sagimet Biosciences Presents Clinical Denifanstat and Preclinical FASN Inhibitor Data at AASLD - The Liver Meeting® 2024

GlobeNewswire

6 months ago

Sagimet Biosciences Presents Clinical Denifanstat and Preclinical FASN Inhibitor Data at AASLD - The Liver Meeting® 2024

Institutional investors in Sagimet Biosciences Inc. (NASDAQ:SGMT) see US$36m decrease in market cap last week, although long-term gains have benefitted them.

Simply Wall St.

6 months ago

Institutional investors in Sagimet Biosciences Inc. (NASDAQ:SGMT) see US$36m decrease in market cap last week, although long-term gains have benefitted them.

Sagimet Biosciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates

GlobeNewswire

6 months ago

Sagimet Biosciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates

Sagimet Biosciences to Participate in the UBS Global Healthcare Conference

GlobeNewswire

6 months ago

Sagimet Biosciences to Participate in the UBS Global Healthcare Conference

Sagimet Biosciences Announces Successful Completion of End-of-Phase 2 Interactions with FDA on the Development of Denifanstat for MASH; Phase 3 Program Initiation Expected by End of 2024

GlobeNewswire

6 months ago

Sagimet Biosciences Announces Successful Completion of End-of-Phase 2 Interactions with FDA on the Development of Denifanstat for MASH; Phase 3 Program Initiation Expected by End of 2024

Sagimet Biosciences Announces Upcoming Presentations at AASLD - The Liver Meeting® 2024

GlobeNewswire

7 months ago

Sagimet Biosciences Announces Upcoming Presentations at AASLD - The Liver Meeting® 2024

Sagimet Biosciences Announces Publication of Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 MASH in The Lancet Gastroenterology & Hepatology

GlobeNewswire

7 months ago

Sagimet Biosciences Announces Publication of Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 MASH in The Lancet Gastroenterology & Hepatology

Sagimet Receives FDA Breakthrough Therapy Designation for Denifanstat in MASH

GlobeNewswire

7 months ago

Sagimet Receives FDA Breakthrough Therapy Designation for Denifanstat in MASH

Sagimet Biosciences to Present at the H.C. Wainwright 8th Annual MASH Virtual Conference and Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

7 months ago

Sagimet Biosciences to Present at the H.C. Wainwright 8th Annual MASH Virtual Conference and Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sagimet Announces Oral Presentation at the 8th Annual MASH Drug Development Summit

GlobeNewswire

8 months ago

Sagimet Announces Oral Presentation at the 8th Annual MASH Drug Development Summit

Sagimet Biosciences to Participate in Two Upcoming Investor Conferences

GlobeNewswire

8 months ago

Sagimet Biosciences to Participate in Two Upcoming Investor Conferences

Sagimet Biosciences Reports Second Quarter 2024 Financial Results and Provides Corporate Updates

GlobeNewswire

9 months ago

Sagimet Biosciences Reports Second Quarter 2024 Financial Results and Provides Corporate Updates

Sagimet Biosciences Announces Appointment of Anne Phillips and Jennifer Jarrett to its Board of Directors

GlobeNewswire

9 months ago

Sagimet Biosciences Announces Appointment of Anne Phillips and Jennifer Jarrett to its Board of Directors

Sagimet Biosciences (NASDAQ:SGMT) Is In A Good Position To Deliver On Growth Plans

Simply Wall St.

a year ago

Sagimet Biosciences (NASDAQ:SGMT) Is In A Good Position To Deliver On Growth Plans

Enhancing the Power of PTZs: Canon Announces New PTZ Firmware Updates Lending Greater Control and Operability, Including an Auto-Tracking Lite Version on Compatible PTZ Models*

GlobeNewswire

a year ago

Enhancing the Power of PTZs: Canon Announces New PTZ Firmware Updates Lending Greater Control and Operability, Including an Auto-Tracking Lite Version on Compatible PTZ Models*

NexTech Solutions Has Agreed to Acquire Rome Research Corporation to Expand Service Offerings and Enhance Mission Support Capabilities

PR Newswire

a year ago

NexTech Solutions Has Agreed to Acquire Rome Research Corporation to Expand Service Offerings and Enhance Mission Support Capabilities

Business Wire

a year ago

Form 8.3 - International Distribution Services plc

Business Wire

a year ago

Form 8.3 - Darktrace plc

US Supreme Court rejects Kroger challenge to Grubhub trademark win

Reuters

a year ago

US Supreme Court rejects Kroger challenge to Grubhub trademark win

Dow Jones Falls As AMD Slides On Downgrade; Nvidia Stock Split Takes Effect

Investor's Business Daily

a year ago

Dow Jones Falls As AMD Slides On Downgrade; Nvidia Stock Split Takes Effect

GoldATM Supports Growing Consumer Demand for Gold Purchase with New ATMs in North Carolina

Business Wire

a year ago

GoldATM Supports Growing Consumer Demand for Gold Purchase with New ATMs in North Carolina

GlobeNewswire

a year ago

Middlefield Canadian Income PCC: Net Asset Value(s)

Sagimet Biosciences to Host Conference Call and Webcast to Discuss Recently Presented Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat

GlobeNewswire

a year ago

Sagimet Biosciences to Host Conference Call and Webcast to Discuss Recently Presented Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat

Sagimet Biosciences Presents Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat at EASL International Liver Congress 2024

GlobeNewswire

a year ago

Sagimet Biosciences Presents Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat at EASL International Liver Congress 2024

Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 23, 2024

GlobeNewswire

a year ago

Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 23, 2024

Sagimet Biosciences Reports First Quarter 2024 Financial Results and Provides Corporate Updates

GlobeNewswire

a year ago

Sagimet Biosciences Reports First Quarter 2024 Financial Results and Provides Corporate Updates

Sagimet Announces Oral Presentation of Data from the Phase 2b FASCINATE-2 Study of Denifanstat in MASH at EASL International Liver Congress 2024

GlobeNewswire

a year ago

Sagimet Announces Oral Presentation of Data from the Phase 2b FASCINATE-2 Study of Denifanstat in MASH at EASL International Liver Congress 2024

Sagimet Biosciences Announces Appointment of Thierry Chauche as Chief Financial Officer

GlobeNewswire

a year ago

Sagimet Biosciences Announces Appointment of Thierry Chauche as Chief Financial Officer

Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 3, 2024

GlobeNewswire

a year ago

Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 3, 2024

Sagimet Biosciences Announces Completion of Phase 1 Hepatic Impairment Study with FASN Inhibitor Denifanstat

GlobeNewswire

a year ago

Sagimet Biosciences Announces Completion of Phase 1 Hepatic Impairment Study with FASN Inhibitor Denifanstat

Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors

GlobeNewswire

a year ago

Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors

Sagimet Biosciences Reports Full Year 2023 Financial Results and Provides Corporate Updates

GlobeNewswire

a year ago

Sagimet Biosciences Reports Full Year 2023 Financial Results and Provides Corporate Updates

Sagimet Biosciences to Participate in Two Upcoming Investor Conferences

GlobeNewswire

a year ago

Sagimet Biosciences to Participate in Two Upcoming Investor Conferences

Blackstone and Other Asset Manager Stocks Have Soared. Earnings Shouldn’t Disappoint.

Barrons.com

a year ago

Blackstone and Other Asset Manager Stocks Have Soared. Earnings Shouldn’t Disappoint.

Sagimet Biosciences Announces Pricing of Public Offering of Series A Common Stock

GlobeNewswire

a year ago

Sagimet Biosciences Announces Pricing of Public Offering of Series A Common Stock

Chuck Royce Reduces Stake in NVE Corp

GuruFocus.com

a year ago

Chuck Royce Reduces Stake in NVE Corp

Associated Press Finance

a year ago

Essa Bancorp: Fiscal Q1 Earnings Snapshot

ESSA Bancorp, Inc. Announces Fiscal First Quarter 2024 Financial Results

ACCESSWIRE

a year ago

ESSA Bancorp, Inc. Announces Fiscal First Quarter 2024 Financial Results

ON24 Unveils its Next Generation Platform, Unleashing a New Era of AI-powered Intelligent Engagement

Business Wire

a year ago

ON24 Unveils its Next Generation Platform, Unleashing a New Era of AI-powered Intelligent Engagement

Sagimet Biosciences Announces Proposed Public Offering of Series A Common Stock

GlobeNewswire

a year ago

Sagimet Biosciences Announces Proposed Public Offering of Series A Common Stock

Redwire Selected as Strategic Supplier for Blue Origin’s Trailblazing Blue Ring Space Mobility Platform

Business Wire

a year ago

Redwire Selected as Strategic Supplier for Blue Origin’s Trailblazing Blue Ring Space Mobility Platform

Sagimet Biosciences Announces Positive Topline Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 NASH

GlobeNewswire

a year ago

Sagimet Biosciences Announces Positive Topline Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 NASH

EATON VANCE TAX ADVANTAGED DIVIDEND INCOME FUND's Dividend Analysis

GuruFocus.com

a year ago

EATON VANCE TAX ADVANTAGED DIVIDEND INCOME FUND's Dividend Analysis

5 Stocks to Gain From Healthy End-of-Year Retail Sales

Zacks

a year ago

5 Stocks to Gain From Healthy End-of-Year Retail Sales

A Look Back at Specialty Retail Stocks' Q3 Earnings: Petco (NASDAQ:WOOF) Vs The Rest Of The Pack

StockStory

a year ago

A Look Back at Specialty Retail Stocks' Q3 Earnings: Petco (NASDAQ:WOOF) Vs The Rest Of The Pack

MoneyLion Inc. (ML) Is a Great Choice for 'Trend' Investors, Here's Why

Zacks

a year ago

MoneyLion Inc. (ML) Is a Great Choice for 'Trend' Investors, Here's Why

Market Exclusive

a year ago

Weekly Roundup on the Cannabis Sector & Psychedelic Sector

SmartFinancial Sets Dates for Fourth Quarter Earnings Release and Conference Call

GlobeNewswire

a year ago

SmartFinancial Sets Dates for Fourth Quarter Earnings Release and Conference Call

Trinity Capital Inc. Appoints Michael Testa as Chief Financial Officer

PR Newswire

a year ago

Trinity Capital Inc. Appoints Michael Testa as Chief Financial Officer

Ecstasy-for-Medicine Advocate Raises $100 Million

The Wall Street Journal

a year ago

Ecstasy-for-Medicine Advocate Raises $100 Million

If EPS Growth Is Important To You, Business First Bancshares (NASDAQ:BFST) Presents An Opportunity

Simply Wall St.

a year ago

If EPS Growth Is Important To You, Business First Bancshares (NASDAQ:BFST) Presents An Opportunity

Rigetti Announces Public Availability of Ankaa-2 System with a 2.5x Performance Improvement Compared to Previous QPUs

GlobeNewswire

a year ago

Rigetti Announces Public Availability of Ankaa-2 System with a 2.5x Performance Improvement Compared to Previous QPUs

The 3 Hottest Quantum Computing Stocks to Watch in 2024

InvestorPlace

a year ago

The 3 Hottest Quantum Computing Stocks to Watch in 2024

RiverNorth Closed-End Funds Declare Monthly Distributions

Business Wire

a year ago

RiverNorth Closed-End Funds Declare Monthly Distributions

Does Marine Products (NYSE:MPX) Deserve A Spot On Your Watchlist?

Simply Wall St.

a year ago

Does Marine Products (NYSE:MPX) Deserve A Spot On Your Watchlist?

Village Super Market (NASDAQ:VLGE.A) Is Paying Out A Dividend Of $0.25

Simply Wall St.

a year ago

Village Super Market (NASDAQ:VLGE.A) Is Paying Out A Dividend Of $0.25

FuelCell Energy (FCEL) Reports Q4 Earnings: What Key Metrics Have to Say

Zacks

a year ago

FuelCell Energy (FCEL) Reports Q4 Earnings: What Key Metrics Have to Say

Pioneer Closed End Funds Required Notice to Shareholders Sources of Distribution Under Section 19(a)

Business Wire

a year ago

Pioneer Closed End Funds Required Notice to Shareholders Sources of Distribution Under Section 19(a)

Acme United Corporation Board Increases Cash Dividend 7 Percent To $0.15 Per Share

GlobeNewswire

a year ago

Acme United Corporation Board Increases Cash Dividend 7 Percent To $0.15 Per Share

An Intrinsic Calculation For Unisys Corporation (NYSE:UIS) Suggests It's 44% Undervalued

Simply Wall St.

a year ago

An Intrinsic Calculation For Unisys Corporation (NYSE:UIS) Suggests It's 44% Undervalued

Sidoti Events, LLC's Virtual December Small-Cap Conference

ACCESSWIRE

a year ago

Sidoti Events, LLC's Virtual December Small-Cap Conference

Sagimet Biosciences to Participate in the First Annual Goldman Sachs Catalyst Clinic

GlobeNewswire

a year ago

Sagimet Biosciences to Participate in the First Annual Goldman Sachs Catalyst Clinic

Sagimet Biosciences Announces Oral Presentation of Preclinical Results of FASN Inhibitor in Combination with Semaglutide at the 7th Obesity and NASH Drug Development Summit

GlobeNewswire

a year ago

Sagimet Biosciences Announces Oral Presentation of Preclinical Results of FASN Inhibitor in Combination with Semaglutide at the 7th Obesity and NASH Drug Development Summit

SpringWorks Therapeutics Announces FDA Approval of OGSIVEO™ (nirogacestat) as the First and Only Treatment for Adults with Desmoid Tumors

GlobeNewswire

a year ago

SpringWorks Therapeutics Announces FDA Approval of OGSIVEO™ (nirogacestat) as the First and Only Treatment for Adults with Desmoid Tumors

4 Best Breakout Stocks to Invest in for Solid Returns

Zacks

a year ago

4 Best Breakout Stocks to Invest in for Solid Returns

Sagimet Biosciences to Present at the 35th Annual Piper Sandler Healthcare Conference

GlobeNewswire

a year ago

Sagimet Biosciences to Present at the 35th Annual Piper Sandler Healthcare Conference

A-Mark Precious Metals Increases Share Repurchase Program

GlobeNewswire

a year ago

A-Mark Precious Metals Increases Share Repurchase Program

STERIS (NYSE:STE) Could Be A Buy For Its Upcoming Dividend

Simply Wall St.

a year ago

STERIS (NYSE:STE) Could Be A Buy For Its Upcoming Dividend

Sagimet Biosciences Reports Third Quarter 2023 Financial Results and Provides Corporate Updates

GlobeNewswire

a year ago

Sagimet Biosciences Reports Third Quarter 2023 Financial Results and Provides Corporate Updates

Alta Equipment Group Inc. (NYSE:ALTG) Q3 2023 Earnings Call Transcript

Insider Monkey

a year ago

Alta Equipment Group Inc. (NYSE:ALTG) Q3 2023 Earnings Call Transcript

Bridge Investment Group Holdings Inc. (NYSE:BRDG) Doing What It Can To Lift Shares

Simply Wall St.

a year ago

Bridge Investment Group Holdings Inc. (NYSE:BRDG) Doing What It Can To Lift Shares

Sagimet Biosciences Presents Preclinical Results Supporting the Therapeutic Potential of its FASN inhibitor in Combination with Semaglutide and a Comprehensive Lipidomic Analysis of Interim FASCINATE-2 Data at AASLD - The Liver Meeting® 2023

GlobeNewswire

a year ago

Sagimet Biosciences Presents Preclinical Results Supporting the Therapeutic Potential of its FASN inhibitor in Combination with Semaglutide and a Comprehensive Lipidomic Analysis of Interim FASCINATE-2 Data at AASLD - The Liver Meeting® 2023

scPharmaceuticals Inc. Reports Third Quarter 2023 Financial Results and Provides Business Update

GlobeNewswire

2 years ago

scPharmaceuticals Inc. Reports Third Quarter 2023 Financial Results and Provides Business Update

IperionX Completes US$16.7M Placement to Re-shore U.S. Titanium Production

Business Wire

2 years ago

IperionX Completes US$16.7M Placement to Re-shore U.S. Titanium Production

Ceragon Networks to Participate in the Needham Virtual Security, Networking, & Communications Conference

PR Newswire

2 years ago

Ceragon Networks to Participate in the Needham Virtual Security, Networking, & Communications Conference

Janux Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights

Business Wire

2 years ago

Janux Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights

Ceragon Networks Ltd. (NASDAQ:CRNT) Q3 2023 Earnings Call Transcript

Insider Monkey

2 years ago

Ceragon Networks Ltd. (NASDAQ:CRNT) Q3 2023 Earnings Call Transcript

Associated Press Finance

2 years ago

Ceragon: Q3 Earnings Snapshot

Northwest Pipe Company (NASDAQ:NWPX) Q3 2023 Earnings Call Transcript

Insider Monkey

2 years ago

Northwest Pipe Company (NASDAQ:NWPX) Q3 2023 Earnings Call Transcript

Ranger Energy Services, Inc. (NYSE:RNGR) Looks Like A Good Stock, And It's Going Ex-Dividend Soon

Simply Wall St.

2 years ago

Ranger Energy Services, Inc. (NYSE:RNGR) Looks Like A Good Stock, And It's Going Ex-Dividend Soon

Thomson Reuters StreetEvents

2 years ago

Q3 2023 Northwest Pipe Co Earnings Call

With 82% ownership, Northwest Pipe Company (NASDAQ:NWPX) boasts of strong institutional backing

Simply Wall St.

2 years ago

With 82% ownership, Northwest Pipe Company (NASDAQ:NWPX) boasts of strong institutional backing

Northwest Pipe Co (NWPX) Reports Q3 2023 Earnings, Announces $30M Share Repurchase Program

GuruFocus.com

2 years ago

Northwest Pipe Co (NWPX) Reports Q3 2023 Earnings, Announces $30M Share Repurchase Program

scPharmaceuticals to Announce Third Quarter 2023 Financial Results on Wednesday, November 8, 2023

GlobeNewswire

2 years ago

scPharmaceuticals to Announce Third Quarter 2023 Financial Results on Wednesday, November 8, 2023

scPharmaceuticals to Participate in Two Upcoming Investor Conferences

GlobeNewswire

2 years ago

scPharmaceuticals to Participate in Two Upcoming Investor Conferences

Share on Social Networks: